• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2023 Fiscal Year Final Research Report

Invovlvement of increased vascular permeability in bortezomib-induced lung toxicity

Research Project

  • PDF
Project/Area Number 21K06703
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 47060:Clinical pharmacy-related
Research InstitutionOur Lady of the Snow Social Medical Corporation (St. Mary (2023)
Fukuoka University (2021-2022)

Principal Investigator

Matsumoto Taichi  社会医療法人 雪の聖母会(聖マリア研究センター), 基礎医学研究ユニット, 上級研究員 (80570803)

Co-Investigator(Kenkyū-buntansha) 松本 純一  福岡大学, 薬学部, 助教 (10550064)
寺田 一樹  姫路獨協大学, 薬学部, 准教授 (00724197)
青木 光希子  福岡大学, 医学部, 講師 (80469379)
自見 至郎  福岡大学, 公私立大学の部局等, 研究特任教授 (30226360)
Project Period (FY) 2021-04-01 – 2024-03-31
Keywords薬剤性肺障害 / ボルテゾミブ / 細胞間接着因子
Outline of Final Research Achievements

In this study, we attempted to elucidate the pathogenesis of bortezomib (BTZ)-induced lung injury. In vitro experiments using monolayer cultures of human alveolar capillary endothelial cells (HPMECs) suggested that BTZ-induced vascular permeability was associated with decreased expression of molecules that control adhesion between vascular endothelial cells, such as Claudin-5, Occludin, and VE-cadherin. In vivo experiments using BTZ-induced lung injury model mice showed that the pathology of BTZ-induced lung injury changed over time, with interstitial lung disease accompanied by inflammation of the alveolar interstitium occurring early after BTZ administration, followed by obstructive lung disease accompanied by destruction of the lung parenchyma.

Free Research Field

薬剤性肺障害

Academic Significance and Societal Importance of the Research Achievements

本研究から、BTZによる血管透過性亢進が起点となり、病態が経時的に変化し、BTZ投与初期には肺胞間質の炎症と伴う間質性肺疾患が起こり、その後、肺実質の破壊を伴う閉塞性肺疾患が出現することが示唆された。したがって、BTZ誘発性肺障害の治療または予防には、BTZによる血管透過性亢進の抑制が重要であると考えられた。BTZによる細胞間接着因子発現抑制作用の詳細なメカニズム解明により、BTZ誘発性肺障害の治療または予防の新規標的分子の同定につながると期待される。

URL: 

Published: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi